|
시장보고서
상품코드
1907955
세프타지딤 아비박탐 시장 : 유형별, 적응증별, 제형별, 약제유형별, 최종 사용자별, 유통 채널별, 지역별Ceftazidime Avibactam Market, By Type, By Indication, By Dosage Form, By Drug Type, By End User, By Distribution Channel, By Geography |
||||||
세프타지딤 아비박탐 시장은 2025년 34억 3,000만 달러로 평가되었고, 2032년까지 59억 2,000만 달러에 이를 것으로 예측됩니다. 2025년부터 2032년까지 8.1%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 시장 규모(2025년) | 34억 3,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측기간 CAGR(2025-2032년) | 8.10% | 예측 금액(2032년) | 59억 2,000만 달러 |
세계의 세프타지딤 아비박탐 시장은 첨단 항균 치료제 분야에서 중요한 부분을 차지하고 있으며, 다제 내성 세균 감염증이라는 증대하는 과제에 대응하고 있습니다. 세프타지딤 아비박탐은 3세대 세팔로스포린계 항균제인 세프타디뮴과 베타-락탐분해효소 억제제인 아비박탐을 조합한 신규 복합 항균제이며, 그람 음성균에 의한 복잡성 복강내 감염증, 복잡성 요로 감염증 및 원내 폐렴에 대한 획기적인 치료 옵션으로
이 혁신적인 치료 조합은 carbapenem 내성 장내 세균과 박테리아(CRE) 및 기타 광역 스펙트럼 베타-락탐분해효소 억제제 생산 박테리아에 대한 효과 향상을 보여 주며 항균제 내성 대책에서 중요한 도구로서의 지위를 확립합니다. 시장에는 병원 약국, 소매 약국, 온라인 플랫폼 등 다양한 투여 형태, 용량 강도 및 유통 경로가 존재합니다. 의료 관련 감염증 증가, 항균제 적정 사용 프로그램에 대한 의식의 높아짐, 항균약 연구개발에 대한 투자 확대에 따라, 세프타지딤 아비박탐 시장은 세계적으로 확대를 계속하고 있습니다. 주요 시장 진출기업은 특히 집중치료실과 면역 결핍 환자 집단에서 내성균 감염증 치료에 있어서 큰 미충족 요구를 파악하기 위해 전략적 제휴, 규제 당국의 승인 취득, 시장 침투 전략에 주력하고 있습니다.
시장 역학
세계 세프타지딤 아비박탐 시장은 주로 세계의 다제 내성 세균 감염증의 만연, 특히 카바페넴 내성 장내 세균과 세균(CRE)이나 광역 스펙트럼 β-락타마제(ESBL) 생산 병원체에 의한 임상 현장에서 중대한 치료 과제의 심각화에 의해 견인되고 있습니다. 의료 관련 감염 증가, 복잡한 감염에 걸리기 쉬운 노인 인구 증가, 의료 종사자의 항균제 내성 패턴에 대한 인식 증가가 시장 수요를 크게 뒷받침하고 있습니다. 항균제 적정 사용 프로그램을 추진하는 정부의 대처, 감염증 조사에의 비용 투자, 신규 항균 요법에 대한 유리한 상환 정책이 시장의 성장을 더욱 가속화하고 있습니다. 또한 신흥국의 병원 인프라 확충과 박테리아 식별을 위한 첨단 진단 기술의 채택 증가도 시장 확대에 기여하고 있습니다.
그러나 항균제 창출과 관련된 높은 개발 비용, 항생제 승인의 엄격한 규제 요건, 잠재적인 부작용으로 인한 환자 규정 준수 제한 등 시장에는 큰 제약이 있습니다. 대체 치료법의 출현, 기존 항생제로부터의 제네릭 경쟁, 장기 사용에 수반하는 내성균 발생에 대한 우려가 더욱 과제가 되고 있습니다. 건강 관리 시스템의 가격 압력과 제한적인 시장 독점 기간도 시장 성장을 제한하는 요인입니다.
그러나, 소아 환자층에의 적용 확대, 외래 치료용 경구 제제의 개발, 제약 기업과 연구 기관과의 전략적 제휴, 미개척 지역 시장에의 진출을 통해, 큰 기회가 존재합니다. 복합 요법에 대한 관심이 증가하고, 감염 관리에 대한 개인화된 의료 접근법, 항균제 연구에 대한 투자 증가는 효과적인 항감염 치료의 세계적인 중요 요구를 충족시키려는 시장 선수들에게 큰 성장 가능성을 보여줍니다.
이 보고서의 주요 특징
- 본 보고서는 세계의 세프타지딤 아비박탐 시장을 상세하게 분석하고, 2024년을 기준 연도로 한 예측기간(2025-2032년) 시장 규모 및 CAGR을 제공합니다.
- 또한 각 부문의 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 행렬을 설명합니다.
- 또한 시장 성장 촉진요인 및 억제요인과 기회, 신제품의 상시와 승인, 시장 동향, 지역별 전망, 주요기업이 채택하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 세계 세프타지딤 아비박탐 시장의 주요 기업 프로파일은 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 다음 매개변수를 기반으로 게재됩니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전술에 대한 충분한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 세계 세프타지딤 아비박탐 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자들은 세계의 세프타지딤 아비박탐 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
- 분석 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- Porter's Five Forces 분석
- 기업 합병 및 인수(M&A) 시나리오
- 업계 동향
제4장 세계의 세프타지딤 아비박탐 시장 : 유형별(2020-2032년)
- 복합제(CAZ/AVI)
- 세프타지딤(CAZ)
- 아비박탐(AVI)
제5장 세계의 세프타지딤 아비박탐 시장 : 적응증별(2020-2032년)
- 복잡성 복강내 감염
- 복잡성 요로 감염
- 병원획득 세균성 폐렴
- 인공호흡기 관련 세균성 폐렴
- 카바페넴 내성균에 의한 혈류 감염
- 기타 다제 내성 그람 음성균 감염
제6장 세계의 세프타지딤 아비박탐 시장 : 제형별(2020-2032년)
- 주사제
- 재구성용 분말
- 프리필드 주사기
제7장 세계의 세프타지딤 아비박탐 시장 : 약제유형별(2020-2032년)
- 브랜드
- 제네릭
제8장 세계의 세프타지딤 아비박탐 시장 : 최종 사용자별(2020-2032년)
- 3차 의료 병원
- 2차 의료 병원
- 장기급성기의료시설
- 전문 감염증 센터
제9장 세계의 세프타지딤 아비박탐 시장 : 유통 채널별(2020-2032년)
- 병원 약국
- 소매 약국
- 온라인 약국
제10장 세계의 세프타지딤 아비박탐 시장 : 지역별(2020-2032년)
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제11장 경쟁 구도
- Pfizer
- Allergan
- AbbVie
- Merck &Co
- Cipla
- Aurobindo Pharma
- Sun Pharmaceutical Industries
- Lupin Pharmaceuticals
- Hikma Pharmaceuticals
- Sandoz
- Fresenius Kabi
- Dr Reddy's Laboratories
- Zydus Lifesciences
- Baxter International
- Teva Pharmaceutical Industries
제12장 애널리스트의 제안
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map(COM)
제13장 참고문헌과 분석 방법
- 참고문헌
- 분석 방법
- Coherent Market Insights에 대해
Ceftazidime Avibactam Market is estimated to be valued at USD 3.43 Bn in 2025 and is expected to reach USD 5.92 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.43 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 8.10% | 2032 Value Projection: | USD 5.92 Bn |
The global ceftazidime avibactam market represents a critical segment within the advanced antimicrobial therapeutics landscape, addressing the growing challenge of multidrug-resistant bacterial infections. Ceftazidime Avibactam, a novel combination antibiotic comprising ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor), has emerged as a breakthrough treatment option for complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia caused by gram-negative bacteria.
This innovative therapeutic combination demonstrates enhanced efficacy against carbapenem-resistant Enterobacteriaceae and other extended-spectrum beta-lactamase producing organisms, positioning it as a vital tool in combating antimicrobial resistance. The market encompasses various formulations, dosage strengths, and distribution channels across hospital pharmacies, retail pharmacies, and online platforms. With increasing prevalence of healthcare-associated infections, rising awareness about antibiotic stewardship programs, and growing investment in antimicrobial research and development, the ceftazidime avibactam market continues to expand globally. Key market participants focus on strategic collaborations, regulatory approvals, and market penetration strategies to capitalize on the substantial unmet medical need in treating resistant bacterial infections, particularly in intensive care units and immunocompromised patient populations.
Market Dynamics
The global ceftazidime avibactam market is primarily driven by the escalating prevalence of multidrug-resistant bacterial infections worldwide, particularly carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase (ESBL) producing pathogens that pose significant therapeutic challenges in clinical settings. The increasing incidence of healthcare-associated infections, rising geriatric population susceptible to complex infections, and growing awareness among healthcare professionals about antimicrobial resistance patterns fuel market demand significantly. Government initiatives promoting antimicrobial stewardship programs, substantial investments in infectious disease research, and favorable reimbursement policies for novel antimicrobial therapies further accelerate market growth. Additionally, expanding hospital infrastructure in emerging economies and increasing adoption of advanced diagnostic techniques for bacterial identification contribute to market expansion.
However, the market faces considerable restraints including high development costs associated with antimicrobial drug discovery, stringent regulatory requirements for antibiotic approvals, and potential side effects leading to limited patient compliance. The emergence of alternative treatment modalities, generic competition from existing antibiotics, and concerns regarding antibiotic resistance development with prolonged usage pose additional challenges. Price pressures from healthcare systems and limited market exclusivity periods further constrain market growth.
Nevertheless, significant opportunities exist through expanding applications in pediatric populations, development of oral formulations for outpatient treatment, strategic partnerships between pharmaceutical companies and research institutions, and penetration into untapped geographical markets. The growing focus on combination therapies, personalized medicine approaches in infectious disease management, and increasing investment in antimicrobial research present substantial growth prospects for market players seeking to address the critical global need for effective anti-infective treatments.
Key Features of the Study
- This report provides in-depth analysis of the global ceftazidime avibactam market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ceftazidime avibactam market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer, Allergan, AbbVie, Merck & Co., Cipla, Aurobindo Pharma, Sun Pharmaceutical Industries, Lupin Pharmaceuticals, Hikma Pharmaceuticals, Sandoz, Fresenius Kabi, Dr. Reddy's Laboratories, Zydus Lifesciences, Baxter International, and Teva Pharmaceutical Industries.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ceftazidime avibactam market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ceftazidime avibactam market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Combination (CAZ/AVI)
- Ceftazidime (CAZ)
- Avibactam (AVI)
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Complicated intra-abdominal infections
- Complicated urinary tract infections
- Hospital-acquired bacterial pneumonia
- Ventilator-associated bacterial pneumonia
- Bloodstream infections caused by carbapenem-resistant organisms
- Other multidrug-resistant Gram-negative infections
- Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Injectable
- Powder for Reconstitution
- Pre-filled Syringes
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Tertiary-care hospitals
- Secondary-care hospitals
- Long-term acute-care facilities
- Specialized infectious disease centers
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer
- Allergan
- AbbVie
- Merck & Co
- Cipla
- Aurobindo Pharma
- Sun Pharmaceutical Industries
- Lupin Pharmaceuticals
- Hikma Pharmaceuticals
- Sandoz
- Fresenius Kabi
- Dr Reddy's Laboratories
- Zydus Lifesciences
- Baxter International
- Teva Pharmaceutical Industries
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Ceftazidime Avibactam Market, By Type
- Global Ceftazidime Avibactam Market, By Indication
- Global Ceftazidime Avibactam Market, By Dosage Form
- Global Ceftazidime Avibactam Market, By Drug Type
- Global Ceftazidime Avibactam Market, By End User
- Global Ceftazidime Avibactam Market, By Distribution Channel
- Global Ceftazidime Avibactam Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Ceftazidime Avibactam Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Combination (CAZ/AVI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ceftazidime (CAZ)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Avibactam (AVI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Ceftazidime Avibactam Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Complicated intra-abdominal infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Complicated urinary tract infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospital-acquired bacterial pneumonia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ventilator-associated bacterial pneumonia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bloodstream infections caused by carbapenem-resistant organisms
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other multidrug-resistant Gram-negative infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Ceftazidime Avibactam Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Powder for Reconstitution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pre-filled Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Ceftazidime Avibactam Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Ceftazidime Avibactam Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Tertiary-care hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Secondary-care hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-term acute-care facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialized infectious disease centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Ceftazidime Avibactam Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Ceftazidime Avibactam Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
11. Competitive Landscape
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fresenius Kabi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Lifesciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Baxter International
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
12. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us
